To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. VWR will not lift restrictions for residential shipping addresses.
Specifications
- Antibody type:Primary
- Clonality:Polyclonal
- Gene ID:83742
- Host:Rabbit
- Isotype:IgG
- Reactivity:Human,Mouse
- Antigen symbol:MARVELD1
- Conjugation:Unconjugated
- ImmunoChemistry:Yes
- Size:100 µg
- Western blot:Yes
- Cross adsorption:No
- Form:liquid
- Antigen synonyms:GB14|MRVLDC1|Putative MARVEL domain containing protein 1|MARVEL membrane-associating domain containing 1|MARVD1|MARVEL domain containing protein 1|MALD1_HUMAN.
- Storage buffer:Aqueous buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.
- Storage temperature:Store at –20 °C for 12 months
- Concentration:1 μg/μl
- Shipping temperature:4°C
- Purification:Purified by Protein A
- Cat. no.:10449-518
- Supplier No.:BS-6548R
Specifications
About this item
MARVELD1, (MARVEL domain-containing 1), is one of the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain-containing proteins. It is a nuclear-localized protein that is widely expressed in normal human tissues. While it has been reported to be overexpressed in colon cancer, MARVELD1 protein levels are generally lower in several primary tumors including ovary, breast, kidney, bladder and liver. This lower level of MARVELD1 expression in tumors is thought to be due to a higher methylation status of the MARVELD1 promoter as treatment of MDA-MB-361 with 5-aza-2'-deoxycytidine restores MARVELD1 expression, suggesting that loss of MARVELD1 expression may contribute to tumorgenicity.
Recommended Dilutions: Western Blot: 1:100-1000; IHC-P: 1:100-500; IF(IHC-P): 1:50-200
Type: Primary
Antigen: MARVELD1
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope:
Host: Rabbit
Isotype: IgG
Reactivity: Human, Mouse